Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARD-501 in Autism Spectrum Disorder
NCT06126653Phase 2Completed
- Sponsor
- Aardvark Therapeutics, Inc.
- Start
- Aug 2024
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ARD-501 in Autism Spectrum Disorder (ASD), sponsored by Aardvark Therapeutics, Inc.. Started Aug 2024; status: completed.
02
Drugs
ARD-501
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on NCT06126653.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06126653.